Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus

OBJECTIVES: To elucidate the mechanism of action of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, and describe immunological pathways related to disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background therapy in a phase II trial. METHODS: Patients with SLE...

Descripción completa

Detalles Bibliográficos
Autores principales: Dörner, Thomas, Tanaka, Yoshiya, Dow, Ernst R, Koch, Alisa E, Silk, Maria, Ross Terres, Jorge A, Sims, Jonathan T, Sun, Zhe, de la Torre, Inmaculada, Petri, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380497/
https://www.ncbi.nlm.nih.gov/pubmed/35609978
http://dx.doi.org/10.1136/annrheumdis-2022-222335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380497/
https://www.ncbi.nlm.nih.gov/pubmed/35609978
http://dx.doi.org/10.1136/annrheumdis-2022-222335

Ejemplares similares